GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novo Nordisk A/S (LTS:0QIU) » Definitions » Cash From Other Investing Activities

Novo Nordisk A/S (LTS:0QIU) Cash From Other Investing Activities : kr0 Mil (TTM As of Dec. 2023)


View and export this data going back to 2009. Start your Free Trial

What is Novo Nordisk A/S Cash From Other Investing Activities?

Cash from other investing activities means the cash received by a company that comes from other investing activities.

Novo Nordisk A/S's cash from other investing activities for the three months ended in Dec. 2023 was kr0 Mil. It means Novo Nordisk A/S received kr0 Mil from other investing activities. Novo Nordisk A/S's cash from other investing activities for the trailing twelve months (TTM) ended in Dec. 2023 was kr0 Mil.

Novo Nordisk A/S Cash From Other Investing Activities Historical Data

The historical data trend for Novo Nordisk A/S's Cash From Other Investing Activities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk A/S Cash From Other Investing Activities Chart

Novo Nordisk A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash From Other Investing Activities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.00 18.00 4.00 - -

Novo Nordisk A/S Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash From Other Investing Activities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7,075.00 - - - -

Novo Nordisk A/S Cash From Other Investing Activities Calculation

Cash from other investing activities means the cash received by a company that comes from other investing activities.

Cash From Other Investing Activities for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novo Nordisk A/S Cash From Other Investing Activities Related Terms

Thank you for viewing the detailed overview of Novo Nordisk A/S's Cash From Other Investing Activities provided by GuruFocus.com. Please click on the following links to see related term pages.

Novo Nordisk A/S (LTS:0QIU) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novo Nordisk A/S (LTS:0QIU) » Definitions » Cash From Other Investing Activities
Comparable Companies
OCSE:GMAB OCSE:ZEAL OCSE:ALK B OCSE:BAVA OCSE:GUBRA OCSE:PEG VRTX REGN ASX:CSL XKRX:207940 MRNA XKRX:068270 XBRU:ARGX XBRU:UCB BNTX ALNY BGNE BMRN SZSE:300122 RPRX
Traded in Other Exchanges
NONOF:USA NVO:USA NOVOB:Mexico NVO:Mexico NOVOBc:UK NOVO B:Denmark NOV:Germany N1VO34:Brazil NNO2:Austria
Address
Novo Alle 1, Bagsvaerd, DNK, DK-2880
Website
https://www.novonordisk.com
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Novo Nordisk A/S (LTS:0QIU) Headlines

No Headlines